Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Cyclophosphamide Injection Generic Name & Formulations
Legal Class
Rx
General Description
Cyclophosphamide 500mg, 1g, 2g; per vial; pwd for inj after reconstitution; preservative-free.
Pharmacological Class
Alkylating agent.
See Also
How Supplied
Contact supplier
Manufacturer
Cyclophosphamide Injection Indications
Indications
Carcinoma of the breast.
Cyclophosphamide Injection Dosage and Administration
Adult
Initially 40–50mg/kg IV in divided doses over 2–5 days; or 10–15mg/kg IV every 7–10 days; or 3–5mg/kg IV twice weekly.
Children
See full labeling.
Cyclophosphamide Injection Contraindications
Contraindications
Severe bone marrow depression.
Cyclophosphamide Injection Boxed Warnings
Not Applicable
Cyclophosphamide Injection Warnings/Precautions
Warnings/Precautions
Leukopenia. Thrombocytopenia. Tumor cell infiltration of bone marrow. Previous X-ray therapy or cytotoxic chemotherapy. Impaired renal or hepatic function. Infections. Adrenalectomy. General anesthesia within 10 days of therapy. Monitor hematologic profile (esp. neutrophils and platelets). Obtain urine sample (monitor for hemorrhagic cystitis); maintain adequate hydration. May interfere with wound healing. Elderly. Pregnancy (Cat.D). Nursing mothers: not recommended.
Cyclophosphamide Injection Pharmacokinetics
See Literature
Cyclophosphamide Injection Interactions
Interactions
Potentiated by phenobarbital. Potentiates other myelosuppressives, radiotherapy, succinylcholine. May potentiate doxorubicin-induced cardiotoxicity.
Cyclophosphamide Injection Adverse Reactions
Adverse Reactions
GI upset, alopecia, leukopenia, infections, thrombocytopenia, anemia, hemorrhagic cystitis (discontinue if occurs), renal tubular necrosis, interstitial pulmonary fibrosis, gonadal toxicity (amenorrhea, infertility), anaphylactic reactions.
Cyclophosphamide Injection Clinical Trials
See Literature
Cyclophosphamide Injection Note
Notes
Formerly known under the brand name Cytoxan.
Cyclophosphamide Injection Patient Counseling
See Literature
Cyclophosphamide Injection Generic Name & Formulations
Legal Class
Rx
General Description
Cyclophosphamide 500mg, 1g, 2g; per vial; pwd for inj after reconstitution; preservative-free.
Pharmacological Class
Alkylating agent.
See Also
How Supplied
Contact supplier
Manufacturer
Cyclophosphamide Injection Indications
Indications
Neuroblastoma (disseminated disease).
Cyclophosphamide Injection Dosage and Administration
Adult
Initially 40–50mg/kg IV in divided doses over 2–5 days; or 10–15mg/kg IV every 7–10 days; or 3–5mg/kg IV twice weekly.
Children
See full labeling.
Cyclophosphamide Injection Contraindications
Contraindications
Severe bone marrow depression.
Cyclophosphamide Injection Boxed Warnings
Not Applicable
Cyclophosphamide Injection Warnings/Precautions
Warnings/Precautions
Leukopenia. Thrombocytopenia. Tumor cell infiltration of bone marrow. Previous X-ray therapy or cytotoxic chemotherapy. Impaired renal or hepatic function. Infections. Adrenalectomy. General anesthesia within 10 days of therapy. Monitor hematologic profile (esp. neutrophils and platelets). Obtain urine sample (monitor for hemorrhagic cystitis); maintain adequate hydration. May interfere with wound healing. Elderly. Pregnancy (Cat.D). Nursing mothers: not recommended.
Cyclophosphamide Injection Pharmacokinetics
See Literature
Cyclophosphamide Injection Interactions
Interactions
Potentiated by phenobarbital. Potentiates other myelosuppressives, radiotherapy, succinylcholine. May potentiate doxorubicin-induced cardiotoxicity.
Cyclophosphamide Injection Adverse Reactions
Adverse Reactions
GI upset, alopecia, leukopenia, infections, thrombocytopenia, anemia, hemorrhagic cystitis (discontinue if occurs), renal tubular necrosis, interstitial pulmonary fibrosis, gonadal toxicity (amenorrhea, infertility), anaphylactic reactions.
Cyclophosphamide Injection Clinical Trials
See Literature
Cyclophosphamide Injection Note
Notes
Formerly known under the brand name Cytoxan.
Cyclophosphamide Injection Patient Counseling
See Literature
Cyclophosphamide Injection Generic Name & Formulations
Legal Class
Rx
General Description
Cyclophosphamide 500mg, 1g, 2g; per vial; pwd for inj after reconstitution; preservative-free.
Pharmacological Class
Alkylating agent.
See Also
How Supplied
Contact supplier
Manufacturer
Cyclophosphamide Injection Indications
Indications
Retinoblastoma.
Cyclophosphamide Injection Dosage and Administration
Adult
Initially 40–50mg/kg IV in divided doses over 2–5 days; or 10–15mg/kg IV every 7–10 days; or 3–5mg/kg IV twice weekly.
Children
See full labeling.
Cyclophosphamide Injection Contraindications
Contraindications
Severe bone marrow depression.
Cyclophosphamide Injection Boxed Warnings
Not Applicable
Cyclophosphamide Injection Warnings/Precautions
Warnings/Precautions
Leukopenia. Thrombocytopenia. Tumor cell infiltration of bone marrow. Previous X-ray therapy or cytotoxic chemotherapy. Impaired renal or hepatic function. Infections. Adrenalectomy. General anesthesia within 10 days of therapy. Monitor hematologic profile (esp. neutrophils and platelets). Obtain urine sample (monitor for hemorrhagic cystitis); maintain adequate hydration. May interfere with wound healing. Elderly. Pregnancy (Cat.D). Nursing mothers: not recommended.
Cyclophosphamide Injection Pharmacokinetics
See Literature
Cyclophosphamide Injection Interactions
Interactions
Potentiated by phenobarbital. Potentiates other myelosuppressives, radiotherapy, succinylcholine. May potentiate doxorubicin-induced cardiotoxicity.
Cyclophosphamide Injection Adverse Reactions
Adverse Reactions
GI upset, alopecia, leukopenia, infections, thrombocytopenia, anemia, hemorrhagic cystitis (discontinue if occurs), renal tubular necrosis, interstitial pulmonary fibrosis, gonadal toxicity (amenorrhea, infertility), anaphylactic reactions.
Cyclophosphamide Injection Clinical Trials
See Literature
Cyclophosphamide Injection Note
Notes
Formerly known under the brand name Cytoxan.
Cyclophosphamide Injection Patient Counseling
See Literature
Cyclophosphamide Injection Generic Name & Formulations
Legal Class
Rx
General Description
Cyclophosphamide 500mg, 1g, 2g; per vial; pwd for inj after reconstitution; preservative-free.
Pharmacological Class
Alkylating agent.
See Also
How Supplied
Contact supplier
Manufacturer
Cyclophosphamide Injection Indications
Indications
Adenocarcinoma of the ovary.
Cyclophosphamide Injection Dosage and Administration
Adult
Initially 40–50mg/kg IV in divided doses over 2–5 days; or 10–15mg/kg IV every 7–10 days; or 3–5mg/kg IV twice weekly.
Children
See full labeling.
Cyclophosphamide Injection Contraindications
Contraindications
Severe bone marrow depression.
Cyclophosphamide Injection Boxed Warnings
Not Applicable
Cyclophosphamide Injection Warnings/Precautions
Warnings/Precautions
Leukopenia. Thrombocytopenia. Tumor cell infiltration of bone marrow. Previous X-ray therapy or cytotoxic chemotherapy. Impaired renal or hepatic function. Infections. Adrenalectomy. General anesthesia within 10 days of therapy. Monitor hematologic profile (esp. neutrophils and platelets). Obtain urine sample (monitor for hemorrhagic cystitis); maintain adequate hydration. May interfere with wound healing. Elderly. Pregnancy (Cat.D). Nursing mothers: not recommended.
Cyclophosphamide Injection Pharmacokinetics
See Literature
Cyclophosphamide Injection Interactions
Interactions
Potentiated by phenobarbital. Potentiates other myelosuppressives, radiotherapy, succinylcholine. May potentiate doxorubicin-induced cardiotoxicity.
Cyclophosphamide Injection Adverse Reactions
Adverse Reactions
GI upset, alopecia, leukopenia, infections, thrombocytopenia, anemia, hemorrhagic cystitis (discontinue if occurs), renal tubular necrosis, interstitial pulmonary fibrosis, gonadal toxicity (amenorrhea, infertility), anaphylactic reactions.
Cyclophosphamide Injection Clinical Trials
See Literature
Cyclophosphamide Injection Note
Notes
Formerly known under the brand name Cytoxan.
Cyclophosphamide Injection Patient Counseling
See Literature
Cyclophosphamide Injection Generic Name & Formulations
Legal Class
Rx
General Description
Cyclophosphamide 500mg, 1g, 2g; per vial; pwd for inj after reconstitution; preservative-free.
Pharmacological Class
Alkylating agent.
See Also
How Supplied
Contact supplier
Manufacturer
Cyclophosphamide Injection Indications
Indications
Malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin's disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt's lymphoma. Multiple myeloma. Leukemias: chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia in children (cyclophosphamide given during remission is effective in prolonging its duration). Mycosis fungoides (advanced disease).
Cyclophosphamide Injection Dosage and Administration
Adult
Initially 40–50mg/kg IV in divided doses over 2–5 days; or 10–15mg/kg IV every 7–10 days; or 3–5mg/kg IV twice weekly.
Children
See full labeling.
Cyclophosphamide Injection Contraindications
Contraindications
Severe bone marrow depression.
Cyclophosphamide Injection Boxed Warnings
Not Applicable
Cyclophosphamide Injection Warnings/Precautions
Warnings/Precautions
Leukopenia. Thrombocytopenia. Tumor cell infiltration of bone marrow. Previous X-ray therapy or cytotoxic chemotherapy. Impaired renal or hepatic function. Infections. Adrenalectomy. General anesthesia within 10 days of therapy. Monitor hematologic profile (esp. neutrophils and platelets). Obtain urine sample (monitor for hemorrhagic cystitis); maintain adequate hydration. May interfere with wound healing. Elderly. Pregnancy (Cat.D). Nursing mothers: not recommended.
Cyclophosphamide Injection Pharmacokinetics
See Literature
Cyclophosphamide Injection Interactions
Interactions
Potentiated by phenobarbital. Potentiates other myelosuppressives, radiotherapy, succinylcholine. May potentiate doxorubicin-induced cardiotoxicity.
Cyclophosphamide Injection Adverse Reactions
Adverse Reactions
GI upset, alopecia, leukopenia, infections, thrombocytopenia, anemia, hemorrhagic cystitis (discontinue if occurs), renal tubular necrosis, interstitial pulmonary fibrosis, gonadal toxicity (amenorrhea, infertility), anaphylactic reactions.
Cyclophosphamide Injection Clinical Trials
See Literature
Cyclophosphamide Injection Note
Notes
Formerly known under the brand name Cytoxan.
Cyclophosphamide Injection Patient Counseling
See Literature
